Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 10/20 | 0.67 |
| ▸ | CASP2 | P42575 | 1/20 | 0.59 |
| ▸ | NAAA | Q02083 | 3/20 | 0.55 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.55 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.55 |
| ▸ | PRCP | P42785 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5933219 | 1.00 | EPHX1 (0.67) | EPHX1CASP2NAAAZDHHC20ZDHHC2 | |
| SCHEMBL9533596 | 1.00 | EPHX1 (0.67) | EPHX1CASP2NAAAZDHHC20ZDHHC2 | |
| SCHEMBL5932722 | 1.00 | EPHX1 (0.67) | EPHX1CASP2NAAAZDHHC20ZDHHC2 | |
| SCHEMBL5932682 | 1.00 | EPHX1 (0.67) | EPHX1CASP2NAAAZDHHC20ZDHHC2 | |
| SCHEMBL9532818 | 1.00 | EPHX1 (0.67) | EPHX1CASP2NAAAZDHHC20ZDHHC2 | |
| SCHEMBL5932852 | 1.00 | EPHX1 (0.67) | EPHX1CASP2NAAAZDHHC20ZDHHC2 | |
| SCHEMBL690225 | 0.98 | — | — | |
| SCHEMBL687620 | 0.90 | — | — | |
| SCHEMBL9615037 | 0.87 | KDM4E (0.52) | EPHX1CASP2 | |
| SCHEMBL12807564 | 0.87 | KDM4E (0.52) | EPHX1CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3214071-B1 | ISOTHIOCYANATE COMPOSITION | ASAHI CHEMICAL IND (JP) | 2019-07-03 | — | — | EP | disclosed |
| EP-1953148-B1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-7915267-B2 | Heterocyclic amide compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-29 | — | — | US | disclosed |
| US-20090137603-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1953148-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20060088786-A1 | Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus | MITSUI CHEMICALS, INC. (JP) | 2006-04-27 | — | — | US | disclosed |
| EP-1130017-B1 | Azole derivatives and their use as superoxide radical inhibitors | OTSUKA PHARMA CO LTD (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-1484191-A1 | REWRITABLE OPTICAL INFORMATION RECORDING MEDIUM AND RECORDING/REPRODUCING METHOD, RECORDING/REPRODUCING DEVICE | Sony Corporation (JP) | 2004-12-08 | — | — | EP | disclosed |
| EP-0934937-B1 | Azole derivatives as superoxide radical inhibitor | OTSUKA PHARMA CO LTD (JP) | 2002-02-27 | — | — | EP | disclosed |
| US-RE37556-E1 | (ALKOXYPHENYL)THIAZOLE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-1130017-A2 | Azole derivatives and their use as superoxide radical inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-05 | — | — | EP | disclosed |
| US-6080764-A | PROTECTING VARIOUS TISSUE CELLS FROM DISTURBANCES ASSOCIATED WITH ISCHEMIA AND BLOOD REPERFUSION IN HEART, BRAIN, KIDNEY, LUNG AND DIGESTIVE TRACT BY INHIBITING SUPEROXIDE-RELEASE BY NEUTROPHILIC LEUKOCYTES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2000-06-27 | — | — | US | disclosed |
| EP-0934937-A1 | Azole derivatives as superoxide radical inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-11 | — | — | EP | disclosed |
| US-5677319-A | THIAZOLE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-10-14 | — | — | US | disclosed |
| US-5643932-A | PREVENTS CELL DAMAGE AFTER ISCHEMIA AND RE-PERFUSION, SUBSTITUTED THIAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-01 | — | — | US | disclosed |
| EP-0513387-A1 | ACTIVE OXYGEN INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060088786-A1 | Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus | ALPG, TRPC6, GNRHR | EPHX1 2778/4885CASP2 2097/4885NAAA 3663/4885 |
| US-20090137603-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | MMP2, MMP9, MMP1 | EPHX1 686/4885CASP2 375/4885NAAA 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.